AZ launches branded YouTube channel, testimonial site

Share this article:

AstraZeneca (AZ) launched a branded YouTube channel today for its asthma drug Symbicort, as well as My Asthma Story (myasthmastory.com), a website calling for testimonial videos.

The YouTube channel and “vlog” (video blog) feature testimonial videos in widescreen, where patients describe their experiences with Symbicort. Some risk information scrolls across the bottom margin of the videos while they play, and a link to full PI information appears near the top of the channel page. Other fair balance information appears elsewhere on the page. The channel also directs consumers to myasthmastory.com, where Symbicort users are invited to upload videos about their own experiences with the drug.

According to Dana Settembrino, senior brand communications manager at AZ, the videos submitted on myasthmastory.com will be reviewed by a panel of legal, regulatory and compliance experts, with their selections appearing on the Symbicort YouTube channel.  Videos appearing on the YouTube channel are not open for comment by viewers.

The YouTube channel and the My Asthma Story website were created by Digitas and Cadient, and allow asthma-sufferers to “share patient stories about controlling asthma,” said Settembrino.  “[The channel and website] is a way to engage patients and maintain a conversation,” she said.

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.